Localized Surface Plasmon Platform for COVID-19 Screening

用于 COVID-19 筛查的局部表面等离子体激元平台

• 批准号: 550059-2020
• 负责人: Brolo, Alexandre
• 金额: $ 3.64万
• 依托单位: University of Victoria
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=701119
• 关键词: Localized; Surface; Plasmon; Platform; COVID

Mass testing is required as an essential tool to help control the COVID-19 pandemic spread. The data already available from Asia (particularly South Korea) emphasizes the role of testing in flattening the rate of infection, precluding health centers and hospitals from being overwhelmed. Currently in Canada, the waiting for test results is around 24 hours and, although a few rapid screening technologies are expected to came on line soon, more alternative technologies for rapid tests are required. Moreover, the demographics of Canada contains several remote and First Nations community that would benefit from on site tests with real-time response. This proposal aims at the development of rapid test for the screening of COVID-19 patients. The technology will be developed in partnership with a Canadian company (ImmunoPrecise Antibodies Canada) that specializes in generating high quality antibodies for different infections and diseases. The technology will be a strip that will change color in contact with COVID-specific proteins from biofluids of infected patients. The interaction will trigger a color change that will be detected in real time with a cell phone.

大规模检测是帮助控制COVID-19大流行传播的必要工具。来自亚洲（特别是韩国）的数据强调了检测在降低感染率方面的作用，防止了卫生中心和医院不堪重负。目前在加拿大，等待检测结果的时间约为24小时，尽管一些快速筛查技术预计将很快上线，但需要更多的快速检测替代技术。此外，加拿大的人口结构中包含几个偏远的原住民社区，这些社区将受益于实时响应的现场测试。 该建议旨在开发用于筛查COVID-19患者的快速检测。该技术将与一家加拿大公司（ImmunoPrecise Antibodies Canada）合作开发，该公司专门生产针对不同感染和疾病的高质量抗体。该技术将是一种试纸，它将在与感染患者生物液体中的COVID特异性蛋白质接触时改变颜色。这种互动将触发一种颜色变化，这种颜色变化将用手机在真实的时间内检测到。